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Abstract. Thyroid cancers (TCs) are the most common
malignancies of endocrine organs. They originate from cells
of different origin within the thyroid gland, which is located
at the base of the neck. Several forms of TCs have been
classified and great variability is observed in molecular,
cellular and clinical features. The most common forms have
favorable prognosis but a number of very aggressive TCs,
which are characterized by a less differentiated cellular
phenotype, have no effective treatment at the moment. While
TC causes are not completely understood, many genetic
factors involved in their onset have been discovered. In
particular, activating mutations of BRAF, RET or RAS genes
are known to be specifically associated with TC initiation,
progression and outcome. The involvement of microRNAs in
thyroid neoplasms has recently changed the paradigm for
biomarker discovery in TC, suggesting that these small non-
coding RNAs could be used to develop, refine or strengthen
strategies for diagnosis and management of TCs. In this
review, the importance of microRNA profiling in TC is
explored suggesting that these molecules can be included in
procedures that can perform better than any known clinical
index in the identification of adverse outcomes. 
Thyroid cancer (TC) is a group of uncommon neoplastic
diseases affecting the thyroid gland. Among carcinomas of
follicular cell origin, three categories of TCs can be defined
according to specific histological features: well-differentiated
thyroid carcinomas (WDTCs), poorly differentiated thyroid
carcinomas (PDTCs) and undifferentiated thyroid carcinomas
(UDTCs) (1). A sequential model in which UDTCs represent
the final step of WDTC progression through the spectrum of
PDTC has been suggested by evidence of pre- or co-existing
WDTCs with less differentiated types that also share the
original genetic alteration (2).
Medullary thyroid cancer (MTC), unlike the previously
mentioned, is a neuroendocrine tumor that arises from
parafolli cular C cell and constitutes types fewer than 5% of
all TC cases (3).
WDTCs are the most common TC forms and include
papillary thyroid carcinoma (PTC), which accounts for about
75-80% of worldwide TC occurrences, and the less frequent
(10-15%) follicular thyroid carcinoma (FTC). PTC
differential diagnosis from FTC is determined by histology.
PTC diagnosis relies on the presence of follicular cell
differen tiation, typically with papillary and follicular
structures, as well as characteristics nuclear changes, such as
large size, pale staining, ‘ground glass’ appearance, irregular
outlines or inconspicuous nucleoli. FTC is characterized by
evidence of follicular differentiation that lacks papillary
architecture and typical nuclear features of PTC (4, 5). Even
if WDTCs are usually considered an homogeneous group of
neoplastic diseases in terms of outcome, follicular cancer is
often more aggressive, leading less favorable survival rates.
On the other hand, much evidence suggests that tumor
histology cannot be considered alone as a determinant of
WDTC prognosis and patient- (e.g. sex and mainly age) and
tumor- (e.g. TNM or size) related factors are usually taken
into account to define risk categories (6-9).
PDTCs are more aggressive than WDTCs and comprise
nonfollicular, nonPTCs. While PDTCs can be easily placed
between differentiated and undifferentiated carcinomas in term
of prognosis, a rigorous and widely accepted histologic
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classification is still contro versial. According to some authors,
they can be classified on the base of two major characteristics:
presence of a solid-trabecular-insular (STI) growth pattern and
absence of conventional nuclear features that define papillary
carcino mas (10, 11). Some authors, on the other hand, propose
histological grading as the only determinant irrespective of
growth pattern (12). Controversial designa tions also arise from
the different thresholds used by authors in defining
classification requirements. Many authors provide evidence of
the impact of different cutoff usage for the identification of
STI areas in comparing prognoses (13). For this reason,
PDTCs can be considered quite rare and heterogeneous tumors
and their prevalence can only be roughly estimated at between
1.5% and 6% of malignant TCs (10, 14).
Anaplastic thyroid carcinoma (ATC) is a highly aggressive
form of UDTC. ATCs constitute the most uncommon sub group
of TCs and are characterized by rapid growth, metasta tic
invasion and, consequently, a dramatically unfavorable
prognosis. The 5-year relative survival rate for anaplastic
carcino ma has been defined at round 7%. All the other forms of
TC have a much better prognosis, with 5-year relative survival
rates of 50% for PDTC (15, 1), 86% for MTC (16) and from
50% to near 100%, according to stage, for WDTCs (17).
Many diagnostic algorithms that evaluate histological, surgi -
cal and molecular features of the thyroid neoplasms can often be
used to easily define TC subgroups and patient risk.
Nevertheless, in some cases, diagnosed TC tumors show
intermediate or confounding profiles that make the classification
more difficult. Some of the above- mentioned disease groups
present intermediate characteristics and comprise tumors that
are heterogeneous for prognosis or sensitivity to treatment.
Many efforts have been made to improve the accuracy of
disease profiling for a better classification of tumors that may
actually behave differently, despite their apparent histological
similarities; however, TC management is still an important
medical challenge. The identification of unambiguous biological
and molecular features that can be used to discriminate indolent
from aggressive disease, for example, would be fundamental in
defining clinically useful predictor risks. On this basis, it is
interesting to note that deregulation of microRNA (miRNA)
function was recently identified as an important driver for tumor
development and progression in TCs (18, 20). miRNAs are a
class of small noncoding RNAs that are able to regulate gene
expression through mRNA cleavage or translational repression.
The specificity of miRNA–mRNA interaction is directed by
nucleotide sequence complementarity between the miRNA seed
region and its corresponding binding sequence on the target
mRNA. The flexibility of this recognition system allows
miRNA to target multiple molecules and mRNAs to be
regulated simulta neously by more than one miRNA, therefore
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Table I. Prevalence, clinicopathological features and most frequent genetic defects of thyroid neoplasms. Genetic alterations are in order of
prevalence from the most to the less frequent.
Tumor type Prevalence Lymph node Distant 5-Year survival Genetic alteration References
metastasis metastasis
PTC 75-80% <50% 5-7% ~ 100% stage I -II BRAF mutation (28, 30, 77, 97,
93% stage III RET rearrangement 98, 99, 101, 102)
51% stage IV NTRK1 rearrangement
RAS mutation
TP53 mutation
(uncommon)
BRAF rearrangement
(uncommon)
FTC 10-15% <5% 20% ~ 100% stage I -II RAS mutation (44, 101, 102)
71% stage III PPARγ
50% stage IV rearrangement
TP53 mutation 
(uncommon)
PDTC <7% 30-80% 30-80% 50% TP53 mutation (28, 30, 98, 99, 101)
RAS mutation
β-Catenin mutation
RET rearrangement
BRAF mutation
UDTC 2% 40% 20-50% 7% TP53 mutation (28, 30, 46, 101)
β-Catenin mutation
RAS mutation
BRAF mutation
MTC <5% 50% 15% 86% RET mutation (100)
PTC: Papillary thyroid carcinoma, FTC: follicular thyroid carcinoma; PDTC: poorly differentiated thyroid carcinoma; UDTC: undifferentiated
thyroid carcinoma; MTC: medullary thyroid carcinoma. 
constituting the basis for a complex and diffused regulatory
network. These molecules finely regulate many biological
processes (including proliferation, apoptosis and differentiation)
and deeply influence pathological pathways (20).
Molecular Biology and Biomarkers of TCs
The growth of follicular thyroid cells is physiologically
regulated by the thyroid-stimulating hormone (TSH or
thyrotropin). TSH receptor, upon thyrotropin binding,
activates the GSα-adenylyl cyclase-cyclic AMP (cAMP)
cascade, triggering cell differentiation and proliferation
through transcriptional activation of specific molecular
effectors. Even though mutations that constitutively activate
TSH receptor or GSα have been identified in 60-70% of
benign adenomas (21-23), the hypothesis of a causative role
in malignant transformations of thyroid cells has been
rejected (24-27). While the constitutive activation of cAMP-
elicited transduction cascade alone is not sufficient for
neoplastic transformation, many genetic abnormalities have
been described in different histological types of TC (Table I).
In WDTCs, the vast majority of cases present genetic
alterations affecting the MAPK signaling pathway. In
particular, activating mutations of BRAF, RET or NTRK1
genes have been identified as causative and mutually
exclusive events in PTC onset. The T1799A transversion
muta tion of BRAF that produces the V600E variant of the
encoded kinase occurs in about 45% of sporadic PTCs (28).
It has been demonstrated that this mutation is associated
with a poorer outcome and it can be used as a predictor of
clinical features, such as extranodal invasion, lymph node
metastasis, advanced staging and disease recurrence (29).
While BRAF mutations have not been found in FTC, they
are present in 13% of PDTC. They have been also observed
more frequently in UDTC with a PTC component than in
those without such a component (30). The expression of
hexogen V600E Braf in mouse thyroid cells produces PTC
with some of the PDTC specific features (31). While the
V600E variant of BRAF is the most common alteration in
sporadic PTC, other variants (e.g. the K601E for the
follicular variant papillary carcino mas and the in-frame
VK600-1E deletion for the solid va riant papillary
carcinoma) define a phenotype specific range of genetic
alterations targeting BRAF exons (32). Much evidences (33-
35) suggests that deregulated activation of the MAPK
cascade can increase genomic instability of TC cells, thus
promoting the acquisition of additional somatic mutations
during TC progression.
The receptor-tyrosine kinase encoded by the RET gene is
an essential molecular actor required for renal organogenesis
and enteric neurogenesis. It has been shown that while gain-
of-function RET mutations are associated with MTC (36), the
chromosomal rearrangements that originate a family of
chimeric RET oncoproteins are involved in PTC development.
At least 10 chimeric PTC- associated RET variants have been
identified in PTC (37) and all of them result from the fusion of
the 3’- terminal sequence of RET that encodes for a tyrosine
kinase domain with the 5’ portion of different genes.
The neurotropic receptor-tyrosine kinase (NTRK1) gene
encodes for a tyrosine-kinase receptor that is activated by NDF.
Its expression is typically neural and usually restricted to
sympathetic, trigeminal and dorsal root ganglia or to cholinergic
neurons of the basal forebrain and the striatum (38). This
receptor, upon NGF binding, trans duces the signal activating
several pathways, including ERK, PI3K and the PLCγ cascades.
NTRK1 rearrangements observed in TC, like those in RET-PTC,
involve the tyrosine kinase domain of NTRK1 that is fused to
another gene. Only three fusion partners, which have practically
identical prevalence in sporadic PTC, have been identified so
far: TFG, TPM3 and TPR. 
RAS mutations are the second most abundant mutations
identified in TCs. They comprise mutations affecting a family of
three homologous isoforms HRAS, KRAS and NRAS, the latter
of which is the most frequently mutated in TC. These
membrane-associated guanine nucleotide-binding proteins
transduce and amplify extracellular signals to initiate important
cellular responses. The type of guanine nucleotide bound to RAS
regulates their activation state: while GTP promotes RAS
activity, GDP inhibits its function. The GTP-ase function of these
proteins promotes their deactivation in a typical feedback
manner: when GDP is bound to RAS, the resulting conformation
is inactive. The physiological role of RAS genes is dual: they are
involved in the activation of both MAPK and PI3K-AKT
pathways. TC-related RAS variants, which predominantly exhibit
mutations of codons 12, 13 and 61, preferentially acti vate the
PI3K-AKT axis as suggested by the observed association
between the occurrence of these mutations and phospho-AKT
increase (39). Oncogenic variants produced by point mutation in
codons 12 and 13 are characterized by increased affinity for
GTP, while those resulting from mutations of codon 61 show
deficiency in the autocatalytic GTP-ase function (40). Among
WDTCs, RAS mutations have been observed more frequently in
tumors with follicular histology (FTC and follicular variant of
PTC) than in typical papil lary TCs (41, 42). In FTC, NRAS
codon 61 mutations are also associated with distant metastasis,
supporting the hypothesis that aber rantly active proteins
participate in providing a more ag gres sive clinical phenotype.
RAS mutations have been observed also in PDTCs and UDTCs
with variable frequencies (1).
Some authors suggested that RAS mutations and
rearrangements involving the peroxisome proliferator-
activated receptor-γ (PPARγ) and paired box 8 (PAX8) genes,
are, in FTC, mutually exclusive events with distinct
molecular mechanisms (43, 44). It has been shown that the
PPARγ gene, which encodes for a steroid nuclear hormone
receptor that forms heterodimers with retinoid X receptor,
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can gene rate a chimeric fusion gene with PAX8, a
transcription factor normally involved in thyroid follicular
cell development. The PPARγ–PAX8 chimera acts as a
negative dominant affecting the transcriptional activity of the
wild type PPARγ gene. The fusion oncoprotein contributes
to malignant transformation in FTC and some authors
indicate that it promotes the vasculo-invasive phenotype. 
Cadherin-associated protein beta 1, encoded by the gene
CTNNB1 and usually called β-catenin, is a protein that by
acts -regulating both cell-cell adhesion and signal
transduction through the Wnt pathway. This transduction
cascade is essential for embryogenesis and integrates signals
from other molecular pathways (retinoic acid, fibroblast
growth factor, transforming growth factor beta 1, bone
morphogenetic protein) within different cell types and
tissues. The cascade starts when the Wnt ligand binds to the
extracellular portion of the Frizzled receptor that in turn
activates a number of molecular partners releasing β-catenin
from its post translational regulation exerted by proteasomal
degradation. The subsequent accumulation of cytosolic β-
catenin allows the protein to translocate to the nucleus where
it promotes the transcription of target genes. Aberrant
expression of β-catenin has been reported in many tumors
(45). Increased cytoplasmic β-catenin is observed in TC but
its increased nuclear localization, which is promoted by
specific mutations, appears to be limited to PDTC and
UDTC (46). Different authors recently reported a clear
functional link between RET oncoprotein activation and the
modulation of downstream β-catenin axis (47, 48).
The overall picture of molecular events involved in TC
initiation and progression has to be completed adding the
fundamental details represented by the regulatory layer
controlled by miRNAs. 
In the recent years, these small endogenous regulators
have been clearly identified as key molecular components in
cancer and tumor miRNA profiles have been shown to be
capable of defining efficiently relevant pathologic subtypes,
patient response and survival.
miRNA as Biomarkers
More than 2,000 miRNAs have been identified in humans
(49). It has been shown that about 50% of human miRNA
genes are located in cancer-associated genomic regions or in
fragile sites (50), supporting their contribution as key drivers
of neoplastic transformation that follows genetic injuries.
Mutations in miRNA target sites that lead to an incorrect
mRNA recognition may induce severe phenotypic
consequences and may promote cancer initiation. (51, 52).
Chromatin remodeling may also affect miRNA expression
through the methylation of promoter sequences. (53).
The first evidence of the role of miRNAs in cancer was
reported for chronic lymphocytic leukemia (54), where the
cluster containing miR-15 and miR-16 is frequently deleted
or down-regulated in cancer cells. During the past decade,
many studies reported that miRNAs are often differentially
modulated in cancer cells, defining severe miRNA
expression patterns that were specifically associated with
histological variants and tumor prognosis (55-58). Moreover,
it has been accepted that miRNAs can be directly controlled
by oncogenic transcription factors (59). 
A common feature of tumor-related miRNA profiles is the
frequent down-regulation of miRNAs in cancer cells, while
their over expression is a much less frequently observed
phenomenon. In physiological conditions, indeed, miRNA
expression increases, as during cell differentiation. Lower
expression levels in cancer cells may be coherent with the
acquisition of a less differentiated state, a common feature
in malignant transformation. The transcriptional inhibition of
miRNA genes in cancer cells can be exerted through
repression by oncogenic transcription factors (60), or through
the alteration of the miRNA biogenesis pathway (61, 62). 
Some authors highlighted the importance of miRNA
biogenesis regulation in TC (63). miRNAs are transcribed
mainly by RNA polymerase II or more rarely by RNA
polymerase III as double-stranded precursors called primary
miRNA (pri-miRNA). These molecules, which are up to
several thousands nucleotides long, are characterized by
distinctive secondary stem-loop structure. Inside the nucleus,
pri-miRNAs are enzymatically cleaved into smaller (70- to
80-nucleotide-long) molecules, defined pre-miRNAs, that
present hairpin structure due to reverse complementary
regions in their sequence. A multicomponent complex called
a microprocessor, whose core components are Drosha and
DGCR8 enzymes, carries out this cleavage. (64). DGCR8
(also known as PASHA in invertebrates) stabilizes the pri-
miRNA, while Drosha, an RNAse type III protein, cuts it
into the pre-miRNA. The pre-miRNAs are then transported
to the cytoplasm by their specific transporter, the exportin-
5, which utilizes nuclear Ran-GTP (65, 66, 20). It is
interesting to note that knockdown of the EXP5 gene, which
encodes for exportin-5, produces a reduction of cytoplasmic
miRNA molecules without an increase of nuclear ones,
suggesting that the transporter may also be involved in pre-
miRNA stabilization and protection from nucleases (67). 
According to the well-known and accepted processing
model, after nuclear export, the pre-miRNA is further
processed by the enzyme Dicer, which recognizes the
terminal loop and after cleavage releases a small RNA
duplex (68). The two strands of these molecules are
defined as the guide strand and the passenger strand
according to the role they will have on the effector
complex for the silencing, which is called RNA-induced
silencing complex (RISC; also referred to as the miRISC).
After pre-miRNA processing, the RISC-loading complex
(RLC), which comprises the Dicer and other molecules,
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catalyses the duplex loading into one of the four Argonauts
(AGO) known in humans. 
The loading mechanism and the dispensability of proteins
that constitute the RLC are still unclear in mammals and
contrasting evidence on RISC assembly has been provided
(69-71). While in flies and in C. elegans the loading process
is specific for the miRNA duplex, which is targeted to
specific AGO proteins according to its sequence, in humans,
a similar system seems not to exist (72). After miRNA
duplex loading, the passenger strand is quickly removed and
its degradation may be exerted by the AGO2 protein through
cleavage, even if cleavage does not seem to be the most
frequent mechanism in miRNA processing. It has been
shown that AGO proteins are stabilized only when they are
bound to miRNA: empty AGO proteins are quickly removed
by proteasome-mediated degradation and autophagy.
As soon as the mature, single-stranded miRNA is in place
inside the RISC complex, it drives the specificity of target
mRNA recognition and subsequent negative regulation.
RISC-mRNA interaction is, in fact, elicited through
nucleotide pairing between the ‘seed’ sequence on the
miRNA and the corresponding complementary ‘seed-match’
sequence on its target mRNA.
A limited complementarity (2-9 nt) between these regions
is sufficient for a functional interaction that usually lead to a
variable degree of mRNA degradation and reduced protein
expression. The partial complementarity between seed and
seed-match sequences permits miRNAs to interact with
several targets. Recent studies showed that non-canonical
pathways of miRNA biogenesis exist, as well as Drosha- and
DGCR8- independent pathway, terminal uridylyl transferase-
dependent (TUTase) pathway and Dicer-independent
pathway. One of the first non-canonical pathways was
identified and demonstrated with experimental procedures
that showed the ability of cells to generate pre-miRNA-like
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Table II. miRNA modulation in thyroid neoplasms. Green boxes indicate
down-regulation, red boxes indicate up-regulation and yellow boxes
indicate conflicting evidence. Define abbreviated terms.
miRNA PTC PDTC FTC ATC MTC References
let-7 nn nn (92, 85, 80, 55)
miR-100 nn (92)
miR-107 nn (92)
miR-122a nn nn (79)
miR-125b nn nn (92, 85, 80)
miR-127 nn nn (93, 79)
miR-128b/b nn (92)
miR-129 nn (79)
miR-130b nn (92)
miR-135b nn (92)
miR-137 nn nn (79)
miR-138 nn nn (91, 87)
miR-139 nn (92)
miR-141 nn nn (92, 96)
miR-142-3p nn (92)
miR-145 nn (92)
miR-146 nn (19, 92)
miR-146b nn nn (79, 80)
miR-148 nn (92)
miR-149 nn (92)
miR-154 nn (92)
miR-155 nn nn (79)
miR-15a nn (92)
miR-17-92 nn (86)
cluster
miR-181a nn (92)
miR-181b nn nn (80)
miR-183 nn nn (79, 96)
miR-185 nn (92)
miR-187 nn (79)
miR-191 nn (93)
miR-192 nn (77)
miR-197 nn (77)
miR-200a nn nn (92, 96)
miR-200b nn nn (92, 96)
miR-200c nn (96)
miR-20a nn (19)
miR-205 nn nn (79)
miR-21 nn nn nn (80)
miR-211 nn (92)
miR-213 nn (92)
miR-216 nn (92)
miR-218 nn (92)
miR-219 nn (87)
miR-221 nn nn nn nn (19, 80, 94, 79)
miR-222 nn nn nn nn (19, 80, 94, 79, 85)
miR-224 nn nn (79)
miR-26a nn nn nn (80, 85)
miR-299 nn (92)
miR-302b nn (92)
miR-302c nn nn (92)
miR-30a-5p nn nn nn (80, 85)
miR-30d nn (80)
miR-31 nn (79)
miR-323 nn (92)
Table II. Continued
Table II. Continued
miRNA PTC PDTC FTC ATC MTC References
miR-328 nn (77)
miR-34a nn (92)
miR-34c nn (92)
miR-345 nn (87)
miR-346 nn (77)
miR-370 nn nn (92, 95)
miR-375 nn (95)
miR-9* nn (95)
miR-96 nn (92)
miR-99a nn (92)
PTC: Papillary thyroid carcinoma, PDTC: poorly differentiated thyroid
carcinoma; FTC: follicular thyroid carcinoma; UDTC: undifferentiated
thyroid carcinoma; MTC: medullary thyroid carcinoma. 
molecules that bind directly AGOs, including AGO2 that
mediates the direct maturation of miRNA (73). An example
of Drosha and DGCR8-independent non-canonical pathway
is represented by the processing of microRNAs located
inside intronic regions (miRtrons) when the introns excised
by the spliceosome are directly cleaved and loaded by Dicer.
Additionally, recent studies identified miRtrons, like miR-
1225 and miR-1228, that are splicing-independent and,
accordingly, have been defined simtron (splicing-independent
mirtron-like miRNAs) (74). It is important to underline that
the functionality of only a small number of these non-
canonical miRNAs processing pathways has been
demonstrated and that further studies are needed to better
understand all the processes involved in miRNA biogenesis.
However, it seems clear at this point that the miRNA
biogenesis pathway will continue to be a rich source of
exciting new discoveries (75).
The identification of miRNAs that may potentially be used
as diagnostic and prognostic markers for TC diagnosis and
treatment will surely provide valuable means to improve TC
management. A considerable degree of observer-related
variability exists in morphological diagnosis of TC, especially
for certain tumor types like follicular pattern neoplasm.
Patient outcome prediction is also biased by this subjective
evaluation and enhancements are desirable to improve
prognosis determination and therapeutic decision making.
One of the main advantages in the use of miRNAs in
practical molecular diagnosis is that these molecules can be
easily identified and profiled through minimally invasive
processes. The active population of mature miRNAs is very
resistant to post-sampling procedures minimizing the risk of
pre-analytical artifacts that may be related to RNA degradation.
Moreover, it has been shown that the concentration of specific
circulating miRNAs in blood is tightly linked to molecular
events occurring in those body regions affected by the disease,
thus providing an indirect, while easy to use, way of measuring
molecular events of diagnostic importance. It was reported
recently that a miRNA-based signature can be used to
discriminate benign from malignant thyroid nodules using fine-
needle aspiration (FNA) samples. The identification of TC-
related miRNAs could also serve to support the discovery of
potential therapeutic targets and the development of more
efficient therapies. 
Many studies have been performed to clarify the role of
aberrant miRNA functions in TCs and most authors ana lyzed
miRNA expression comparing different forms of TCs in
order to identify unique expression patterns (Table II).
In a Chinese study (58), 51 thyroid tumor and adjacent
normal tissues were profiled for the identification of miRNA
signatures that discriminate between PTCs and nodular
goiters (NG). The authors showed that three miRNAs were
significantly associated with PTC: miR-30a-3p, miR-146b
and miR199b-5p and, while the first has been found to be
down-regulated, the others were up-regulated in tumor
tissues. It is obvious that the importance of these profiles in
discriminating tissues is limited to comparisons of the same
type. Some authors (18), for instance, reported a detailed
signature of miRNAs differen tial ly modulated between PTCs
and normal tissues that do not include the three miRNAs
listed above. They also highlighted the importance of miR-
221 using experimental models to evaluate the effects of its
over expression. The same authors also investigated the
expression of miRNAs in ATC and observed that miR-30d,
miR-125b, miR 26a, and miR-30a-5p are drastically down-
regulated in tumor tissues. Cantara and co-workers screened
miRNA expression in sera from PTC, NG and healthy
subjects (76). The analysis revealed eight down-regulated
(579, -95, -29b, 5-01-3p, -548d-5p) and three up-regulated
(190, -362-3p, -518a-5p) miRNAs in PTC when compared
to NG and healthy subjects. After a confirmatory analysis on
a wider cohort, miRNAs 579, 95, 29b and 190 maintained
their significative differen ces among sample types. The
analysis of 45 primary thyroid samples, comprising FTC
samples, follicular adenomas and normal control thyroids
(77), resulted in the identification of two miRNAs
significantly over expressed in FTC: miR-197 and miR-346.
The in vitro over expression of both molecules induced
proliferation, while their inhibition reduced cellular growth,
suggesting an oncogenic role for these miRNAs. In a
subsequent study (78), some authors used a more focused
technology to characterize the expression of a smaller set of
miRNAs in a group of surgically removed thyroid neoplastic
and normal samples and in 62 FNA samples. They identified
a number of molecules that were specifically modulated in
PTC, FTC and ATC. Interestingly, it has been shown that
while some miRNAs are usually over expressed in TC (e.g.
miR-121 and miR-122), the level of their up-regulation is
typical of the pathological phenotype considered. A number
of studies also focused on miRNA profiling in PDTCs (78-
80). It has been shown, for example, that miR-150 and miR-
23b can be used to classify conven tional and oncocytic
PDTC when compared to WDTC (79). Moreover, miR-187,
-221, -129, -222, -146b, -339 and -183 (78) were
significantly over expressed in PDTCs when compared to
normal tissues or hyperplastic nodules.
As mentioned above (1), ATC is likely to arise from PTC
and FTC progression. This process requires multiple changes
in global gene expression and some of the involved molecular
pathways have been already characterized (81-83). According
to their role as master gene regulators, the analysis of miRNA
expression profiles in ATC has often been investigated in
order to elucidate the processes leading to this transition.
Even though a number of studies have been performed and
reported in the literature, ATC is a very rare disease. For this
reason, the data produced so far often lack a strong numeric
basis to statistically support the conclusions drawn by
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authors. In 2007, Visone and co-workers investigated the
genome-wide miRNA expression in 10 human ATCs and
compared it with 10 normal thyroid profiles. While they
proposed a miRNA signature associated with ATC, they also
showed that according to functional studies in vitro, miR125b
and miR-26a down-modulation may be critical for thyroid
carcinogenesis (84). Another study (78) indicate that miR-
302c, -205 and -137 are over expressed in ATC samples when
compared to hyperplastic nodules. Different miRNA
signatures have been proposed to discri minate ATC from
other TCs. It has been shown (85, 86) that the down-
regulation of miR-138 may be sufficient to distin guish ATC
from PTC. It was also recently suggested, also, that the up-
regulation of miR-200 and mR-30 family mem bers can
efficiently discriminate ATC from PTC and FTC. 
MicroRNA for Risk Assessment and TC Prognosis
Many efforts have been made for the identification of
molecular biomarkers that can be easily used for diagnosis,
prog nosis and risk assessment. As previously reported,
miRNAs have been widely studied and sometimes
unequivocally associated with specific types of TCs. Scientific
works that aim to reveal associations between miRNA-altered
expression and clinically relevant features in PTC are not so
numerous but the proposed evidence deserves special atten tion
for their pra ctical relevance. Table III summarizes the
involvement of miRNAs in these phenomena according to
literature published so far.
An observational study was conducted to identify possi ble
associations between deregulated miRNA expression and
clinicopathological features, including BRAF mutational
status, in a Chinese cohort of 52 patients with PTC (87). It
was demonstrated that four miRNAs (221, 222, 146b and
181) had significantly higher expression levels in patients
with BRAF mutations. The transcript levels of miRNA- 221
and miRNA-181 were also higher in patients with tumor
diameter ≥2 cm, while over expression of miRNA-221 and
miRNA-222 was observed in patients with advanced TNM
stage and lymph node metastasis. Another Asian study (88)
comple mented these findings with the identification of a
significantly relevant association between miR-21* and miR-
203 expres sion and some of the above mentioned features
(BRAF mutations, TNM stage and occurrence of lymph node
meta stases). Increased expression of miR-199b-5p in PTC
was also shown to be associated with extrathyroidal exten sion
and lymph node metastasis (58).
The opportunity to use circulating miRNAs as biomarkers
for minimally invasive molecular tests has been also explored
(89) and these small non-coding molecules demonstrated to
be predictive of features, like tumor size, multifocality,
lymph node metastasis and TNM staging. These molecules,
in fact, are very stable in sera and miRNA profiles obtained
after blood sampling are often recognizable and
reproducible. The mechanisms underlying miRNA release
from tissues into the bloodstream, however, is still unclear.
More over, sera-isolated miRNAs are actually released by
many cells belonging to different body regions not all of
which are involved in the pathological process. For these
reasons, blood sampling-based techniques must take into
account the risks for false- positive (e.g. increased miRNA
production by disease -unrelated regions) and false- negative
(i.e. when the event to be monitored is the decrease of tumor-
specific miRNA level) occurrences.
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Table III. miRNA expression profiles associated with specific pathological features. Green boxes indicate down-regulation, while red boxes indicate
up-regulation.
miRNA Aggressive BRAF Extrathyroidal LN Multifocal Relapse- Tumor- Size ≥ TNM stage 
phenotype mutation extension metastasis cancer free survival specific survival 2 cm I/II vs III/IV
hsa-let-7e nn
hsa-miR-130b nn
hsa-miR-146b nn nn
hsa-miR-151-5p nn
hsa-miR-181 nn nn nn nn nn
hsa-miR-199b-5p
hsa-miR-203 nn
hsa-miR-21* nn nn
hsa-miR-221 nn nn nn nn
hsa-miR-222 nn nn nn nn
hsa-miR-23b nn
hsa-miR-34b nn
hsa-miR-99b nn
hsa-miR151-5p nn
hsa-miR-150 nn
The impact of miRNA deregulations in prognosis has been
investigated in different TC types, like PTC, follicular variant
of papillary thyroid carcinoma (FVPTC) and PDTC (90-91,
79). In FVPTC, for example, increased transcription levels of
miR-181 and miR-99b produced a decrease in a 10-year
relapse-free survival from ~75% to ~18% for the former and
from 60% to near 0% for the latter miRNA. On the contrary,
a decrease in miR-23b expression in PDTC is reflected in a
reduced relapse-free survival. While these studies underline
that miRNA profiles can actually perform better than any
known clinical indexes (e.g. tumor necrosis, increased mitotic
index or convoluted nuclei occurrence) in the identification
of adverse outcome, further studies will have to prove their
potential diagnostic and predictive clinical value.
Conclusion
TC exhibits a wide range of clinical behaviors comprising
indolent to highly aggressive forms. While the identification
of genetic injuries, like BRAF, RAS, RET and NTRK1
mutations and rearrangements have greatly aided our
understanding of thyroid cell transformation, in many cases
a clear distinction between risk categories in specific TC
subtypes is far from being achieved. Many studies offered
insights into the stepwise neoplastic progression, providing
molecular signatures that can be ideally used for clinical
management of TC. miRNA profiling adds information of
critical importance to the molecular picture represented by
gene regulation and thus provides completeness and strength
to those signatures. According to the literature cited herein, it
is possible to conclude that while miRNA signatures are
mature enough for TC- type classification, further evidence
is needed to confirm that these molecules can be used as
valuable biomarkers for outcome prediction in thyroid
neoplastic diseases. 
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